Runnymede-Bloor West Village (CA)
{name}
{subtitle}
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
city
~6 mi. (Toronto, Canada, +128 more cities)
facility
Princess Margaret Cancer Centre University Health Network
condition
Multiple Myeloma
drug
bortezomib, +5 more drugs
drug type
cellular therapy, +4 more types
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
city
~6 mi. (Toronto, Canada, +226 more cities)
facility
Princess Margaret Cancer Centre University Health Network
biomarker
EGFR Exon 19 Deletion, +1 more biomarker
condition
Non-Squamous Non-Small Cell Lung Carcinoma
drug
amivantamab, +3 more drugs
drug type
chemotherapy, +1 more type
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
city
~6 mi. (Toronto, Canada, +133 more cities)
facility
Princess Margaret Cancer Centre University Health Network
condition
Multiple Myeloma
drug
bortezomib, +4 more drugs
drug type
chemotherapy, +3 more types
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~6 mi. (Toronto, Canada, +247 more cities)
facility
Local Institution, +1 more facility
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~6 mi. (Toronto, Canada, +89 more cities)
facility
North York General Hospital ( Site 0108), +1 more facility
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
city
~6 mi. (Toronto, Canada, +744 more cities)
facility
Odette Cancer Centre- Sunnybrook Health Sciences Centre, +1 more facility
condition
Breast Carcinoma
drug
axillary lymph node dissection, +1 more drug
drug type
radiation therapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~6 mi. (Toronto, Canada, +226 more cities)
facility
Sunnybrook Research Institute ( Site 0108), +1 more facility
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
city
~6 mi. (Toronto, Canada, +454 more cities)
facility
Hospital for Sick Children, +1 more facility
condition
Classical Hodgkin Lymphoma
drug
brentuximab vedotin, +7 more drugs
drug type
chemotherapy, +3 more types